Mostrar Noticias:

CELGPrincipalesÚltima Hora

 Ver noticias de otros activos

Búsqueda de noticias relacionadas a la acción Celgene Corporati (ordenadas por fecha):

Cinco vías para 'atacar' el sector de la biotecnología elEconomista.es El caso más claro es el de Celgene (CELG.NQ), que mientras que se ha anotado un 4,6% desde el 1 de enero, ha visto caer su PER (veces que el beneficio está contenido en el precio) casi un 2%. Además, es una de las que cuenta con mayor potencial y es la ...

Celgene Corporation to Present at Sanford C. Bernstein's 28th Annual Strategic ... MarketWatch (press release) SUMMIT, NJ, May 22, 2012 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) today announced its presentation at Sanford C. Bernstein's 28th Annual Strategic Decisions Conference on Wednesday, May 30, 2012 at 3:00p.m. EST will be webcast live and will ... y más »

The biggest R&D spenders in biotech FierceBiotech Gilead ($GILD) bought its way into the hot race on hep C. Celgene ($CELG) has been aggressive on its own front, buying Avila and investing in new technology. And Vertex ($VRTX) showed that when you stay aggressive, and smart, you should never be ... y más »

ETF Daily News

ETFs: How To Ride The Surge In Biotech M&A (XBI, IBB, PBE, PFE, CELG, AMGN ... ETF Daily News IBB tracks the Nasdaq Biotechnology Index and focuses on big players like Amgen Inc.(NASDAQ:AMGN) and Celgene Corp. (NASDAQ:CELG). Its expense ratio is 0.48%. One-year return is 28.4% and its year-to-date (YTD) return is nearly 17%. y más »

Zacks Reaffirms Neutral Rating on Celgene (CELG) Junction Report Celgene (NASDAQ: CELG)'s stock had its ?neutral? rating reiterated by Zacks in a research note issued to investors on Friday. They currently have a $74.00 price target on the stock. Zacks' analyst wrote, ?Celgene's first quarter 2012 adjusted earnings ... y más »

Celgene Retains Neutral Rec Zacks.com We are maintaining our Neutral recommendation on Celgene Corporation (CELG - Analyst Report) with a target price of $74.00. Celgene disclosed its first quarter 2012 results last month. The company earned 96 cents on an adjusted basis during the quarter ... y más »

The Star-Ledger - NJ.com

Celgene Q1 Results Miss Estimates; But Reaffirms 2012 Outlook NASDAQ (RTTNews.com) - Integrated biopharmaceutical company Celgene Corp. (CELG) reported Thursday a profit for the first quarter that surged from last year, reflecting lower expenses and double-digit revenue growth amid higher international sales of Revlimid ... Epizyme earns upfront $90 million in deal with Celgene; latter posts 17% sales ...The Pharma Letter Deep Dive Into Today's Trading Activity for Celgene Corporation (CELG)AVAFIN los 47 artículos informativos »

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel MarketWatch (press release) SUMMIT, NJ, May 07, 2012 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at ... y más »

Celgene Corporation to Present at Two Upcoming Investor Conferences MarketWatch (press release) SUMMIT, NJ, May 04, 2012 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company's Web site at ... y más »

FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers Fox Business WASHINGTON ? The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers. Revlimid is approved to treat patients with multiple myeloma, ... FDA Issues Extensive Update About Revlimid And Second CancersThe Myeloma Beacon los 4 artículos informativos »

US FDA Staff Shoot Down Pfizer Rare Disease Drug; Repros Updates Special ... Proactive Investors USA & Canada Celgene Corporation (NASDAQ: CELG) today announced its presentation at Sanford C. Bernstein's 28th Annual Strategic Decisions Conference on Wednesday, May 30, 2012 at 3:00p.m. EST will be webcast live and will be available in the investor relations ...

FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers Wall Street Journal By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers. y más »

Celgene Rating Lowered to Neutral at Bank of America (CELG) Daily Political Celgene (NASDAQ: CELG) was downgraded by equities researchers at Bank of America (NYSE: BAC) from a ?buy? rating to a ?neutral? rating in a report issued on Friday. Shares of Celgene traded down 0.62% during mid-day trading on Friday, hitting $72.925. y más »

Celgene Sets The Stage For Patient Investors Seeking Alpha But Vertex isn't alone in offering shareholders a promising pipeline. Another recently beaten up stock, Celgene (CELG), also may reward patient shareholders. Celgene shares have retreated 13% since peaking a shade above $80 in early April. y más »

Three new rules for biopharma collaborations FierceBiotech At least in oncology, Celgene ($CELG) appears to be winning over collaborators. In one off-the-record conversation, two heads of business development told me that biotechs are warming up to the flexibility and creativity of the Summit, ...

4-Star Stocks Poised to Pop: Celgene DailyFinance By Brian D. Pacampara, The Motley Fool Based on the aggregated intelligence of 180000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene (NAS: CELG) has earned a respected four-star ... y más »

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel Genetic Engineering News (press release) Celgene Corporation (NASDAQ: CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at Celgene and will serve on the company's ... y más »

Celgene Corporation (NASDAQ:CELG) Surprise Investors with Cheerful Profits ... PT News Celgene Corporation (NASDAQ:CELG) reported on Thursday that its profit moved up 57% in the first three months of 2012, but the shares of the company tumbled after its results failed to meet Wall Street forecasts. The company reported that its profit ... Hot Stocks Research for Electronic Arts, Celgene, QUALCOMM, Monster Worldwide ...MarketWatch (press release) los 2 artículos informativos »

Critical Alerts For MasterCard, Celgene, Tempur-Pedic, AstraZeneca, and ... MarketWatch (press release) Today's PriceWatch Alerts cover the following stocks: MasterCard (NYSE:MA) , Celgene (NASDAQ:CELG) , Tempur-Pedic (NYSE:TPX) , AstraZeneca (NYSE:AZN) , and Sotheby's (NYSE:BID) . InvestorsObserver's PriceWatch Alerts contain concise, ... y más »

New England Journal of Medicine Reports on Three Phase III REVLIMID(R ... MarketWatch (press release) BOUDRY, Switzerland, May 10, 2012 (BUSINESS WIRE) -- Celgene International Sarl, a subsidiary of Celgene Corporation (NASDAQ:CELG) , today announced that results from three phase III studies evaluating the use of continuous REVLIMID(R) (lenalidomide) ... New England Journal of Medicine Reports on Three Phase III REVLIMID ...EON: Enhanced Online News (press release) los 20 artículos informativos »

US FDA warns on safety of Celgene's Revlimid; new Ph III trial results The Pharma Letter The US Food and Drug Administration this week issued a notification of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received drugmaker Celgene (Nasdaq: CELG) Revlimid ... y más »

Critical Alerts For General Motors, Celgene, Guess, AOL, and Cognizant ... PR Newswire (press release) Today's PriceWatch Alerts cover the following stocks: General Motors Company (NYSE: GM), Celgene Corporation (Nasdaq: CELG), Guess Inc. (NYSE: GES), AOL Inc. (NYSE: AOL), and Cognizant Technology Solutions Corp. (Nasdaq: CTSH). y más »

Equities Research Analysts' Ratings Reiterations for May, 11st (AAPL, CELG ... Junction Report Celgene (NASDAQ: CELG) had its ?neutral? rating re-affirmed by analysts at Zacks. They now have a $74.00 price target on the stock. Cisco Systems, Inc. (NASDAQ: CSCO) had its ?neutral? rating re-affirmed by analysts at Zacks. y más »

Insiders Bought These Stocks on May-21 Fyxnews Celgene Corp. (NASDAQ:CELG): Fouse Jacqualyn A (see remarks) purchased 1000 shares at a price of $68.92. Celgene Corporation is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies designed to ... y más »

The Definitive Biotech ETF Guide (IBB, XBI, FBT) MarketWatch Beyond that, biotech's Big Four ? Amgen (NASDAQ:AMGN) , Gilead (NASDAQ:GILD) , Celgene (NASDAQ:CELG) and Biogen (nasdq:BIIB) ? account for over a quarter of IBB's weight. Additionally, investors should note nearly 30% of IBB's weight goes to ... y más »

Critical Alerts For MasterCard, Celgene, Tempur-Pedic, AstraZeneca, and ... NEWS.GNOM.ES (press release) Today's PriceWatch Alerts cover the following stocks: MasterCard (NYSE: MA), Celgene (Nasdaq: CELG), Tempur-Pedic (NYSE: TPX), AstraZeneca (NYSE: AZN), and Sotheby's (NYSE: BID). InvestorsObserver's PriceWatch Alerts contain concise, ... y más »

Celgene Misses On Slow Jan. Investor's Business Daily 8. Q1 EPS rose 30% to $1.08, 5 cents shy of estimates. Sales rose 13% to $1.27 bil, under views for $1.32 bil as the biotech cited a "slower-than-expected January." Celgene (CELG)sees '12 earnings per share of $4.70-$4.80, below estimates of $4.83. y más »

UBS Suggest Buying Celgene (CELG) on Pullback; Key Takeaways From Conference Call StreetInsider.com (subscription) [4] Increased granularity around the timing of clinical catalysts for 2012-13." Cutting FY12 EPS estimate from $4.87 to $4.71 and FY13 from $5.80 to $5.53. Shares of Celgene closed at $72.92 yesterday, with a 52 week range of $51.70-$80.42. y más »

2 Pharmaceutical Companies Trading Below Net Cash Seeking Alpha Mr. Gryska is the former Senior Vice President and Chief Financial Officer of Celgene Corporation (CELG). Mr. Brewer and Mr. Gryska collectively have an extensive track record of commercializing, acquiring and marketing pharmaceutical products ...

Wednesday's Stocks To Watch, May 23 2012 Daily Markets (blog) Celgene Corporation (NASDAQ:CELG) bounced nicely off the 200 day MA. If it can clear the recent high of $71.75, I think it can get to the 50 day MA at $75 FirstEnergy Corp. (NYSE:FE) was setting up nicely in this small consolidation pattern and I was ... y más »

Disappointed By Celgene's Q1? Take The Long View Citybizlist (press release) By William Meyers Celgene (CELG), a biopharmaceutical company therapy company, provides a double dose of growth potential: further revenue growth with its currently approved therapies and a rich pipeline with some therapies closing in on FDA approval ...

Sell In May: Further Reflections Seeking Alpha Apple (AAPL), Monster Beverage (MNST), Green Mountain Coffee Roasters (GMCR), and Celgene (CELG). I've included totals with them included and excluded. It seems that the arguments to remove these stocks are stronger than the ones for leaving them in.

Proactive Investors USA & Canada

Research Analysts' Updated EPS Estimates for April, 27th (AEO, BG, CELG, CME ... Junction Report Celgene (NASDAQ: CELG) 's EPS estimates were cut by analysts at UBS AG. They now have a ?buy? rating and a $85.00 price target on the stock. They previously had a $88.00 price target on the stock. CME Group Inc. (NYSE: CME) 's EPS estimates were cut by ... Thursday Post Market Company, Economic and Hedge Fund NewsValueWalk los 31 artículos informativos »

Scripts Holding (NASDAQ:ESRX) Net Slip 18% However Tops Revenue Forecasts ... PT News Merck & Co., Inc (NYSE:MRK) surged +0.79% to settle at $38.39, Walgreen Company (NYSE:WAG) moved up +0.35% to end at $34.05 while Celgene Corporation (NASDAQ:CELG) jumped +0.33% to finish on Thursday at $70.65. Express Scripts Holding Company ... y más »

Celgene Reports Q1 Results: Seeing Further Upside Seeking Alpha Celgene's latest earnings release fits into this category well. Although the company missed on several product fronts in the first quarter, they stated that there was positive momentum heading into the second quarter. The first quarter miss was due to ...

Separating the Bargains From the Busts TheStreet.com I want to buy the decline in Celgene(CELG). Yes, Revlimid, its big drug, was soft in January. But the number of approvals that Celgene has coming up and the reasonable explanations for the Revlimid weakness -- inventory and Medicare Issues -- are now ...

Mass High Tech

Biogen Idec (NASDAQ:BIIB) Reports Q1 Earnings, Revenue Surged 7%- BIIB, ELN ... eStocksDaily Turning towards the sector Amgen, Inc. (NASDAQ:AMGN) lost -0.59%, Celgene Corporation (NASDAQ:CELG) decline -0.47%, Gilead Sciences, Inc. (NASDAQ:GILD) fell -1.11%, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) advanced +1.56%, QUALCOMM, ... Biogen Q1 Earnings Miss Estimates; Outlook In -LineInvestor's Business Daily los 56 artículos informativos »

Active Stock Alerts: HMS Holdings, Celgene, Simon Property, Arkansas Best ... Wall St. Cheat Sheet Celgene Corporation (NASDAQ:CELG): Rodman & Renshaw believes the pullback in shares of Celgene following the company's disappointing Q1 results presents an attractive buying opportunity. The firm maintains an Outperform rating on the stock with a $102 ... y más »

Smart Biotech Management For Clinical Trial Paths Seeking Alpha Here are some examples of such efforts: The Celgene Corporation (CELG) is a global biopharmaceutical company focused on the discovery, development, and commercialization of products used to treat cancer, immune diseases, and inflammatory conditions.

Cerner (NASDAQ:CERN) Records New High on Strong Earning- CERN, CELG, INTC, CAT ... eStocksDaily Turning towards the sector Celgene Corporation (NASDAQ:CELG) rose +0.63%, Intel Corporation (NASDAQ:INTC) added +0.57%, Caterpillar Inc. (NYSE:CAT) grew +0.16%, Microsoft Corporation (NASDAQ:MSFT) dropped -0.40%, QUALCOMM, Inc. (NASDAQ:QCOM) which ... y más »